Andrew Waters

17PUBLICATIONS
152CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Oct 08, 2026
Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS -mutant Pancreatic and Lung Cancer.

|Aug 11, 2026
RAS Inhibitor RMC-7977 Blocks Vascular Overgrowth of NRASQ61R Mutant Endothelial Cells.

|Nov 17, 2025
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.

Szu-Aun Long, Haley Todd, Grace Goodhart

|Sep 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer.

Priya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp

|Dec 05, 2024
Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells.

Ian M Loveless, Samantha B Kemp, Kailee M Hartway

|May 31, 2024
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers.

Daniel P Nussbaum, Colin A Martz, Andrew M Waters

Pageof 3

Frequent Collaborators

12 joint publications

Channing J Der

8 joint publications

Adrienne D Cox

7 joint publications

G Aaron Hobbs

7 joint publications

Kirsten L Bryant